Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | YAP1 | P46937 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18986857 | 0.88 | GPR119 (0.50) | JAK2JAK1GPR119NR1H2USP30 | |
| SCHEMBL18986855 | 0.88 | GPR119 (0.50) | JAK2JAK1GPR119NR1H2USP30 | |
| SCHEMBL18986856 | 0.88 | GPR119 (0.50) | JAK2JAK1GPR119NR1H2USP30 | |
| SCHEMBL20588384 | 0.87 | JAK2 (0.47) | JAK2JAK1GPR119STSKDM4E | |
| SCHEMBL9938446 | 0.84 | PRMT5 (0.51) | JAK2JAK1GPR119STSNR1H2 | |
| SCHEMBL6095209 | 0.83 | JAK2 (0.53) | JAK2JAK1GPR119STSNR1H2 | |
| SCHEMBL30993456 | 0.83 | JAK2 (0.53) | JAK2JAK1GPR119STSNR1H2 | |
| SCHEMBL31288410 | 0.83 | JAK2 (0.53) | JAK2JAK1GPR119STSNR1H2 | |
| SCHEMBL18986859 | 0.83 | PDPK1 (0.45) | SMN1; SMN2HSD11B1 | |
| SCHEMBL2978399 | 0.81 | BACE1 (0.49) | JAK2JAK1GPR119STSKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368112-B | Therapeutic compounds, compositions, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3390402-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-10-24 | — | — | EP | disclosed |
| EP-3390396-A1 | ISOINDOLE COMPOUNDS | Astrazeneca AB (SE) | 2018-10-24 | — | — | EP | disclosed |
| US-20180297997-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2017102784-A9 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2018-04-05 | — | — | WO | disclosed |
| WO-2017102784-A1 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017103188-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885GPR119 1598/4885 |
| US-20180297997-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885GPR119 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.